GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of reading triple agonist threads from 2024 and half of it aged badly — 64 comments in the full submission. View in context.
6.4k
c/retatrutide·submitted 2 years ago by u/source_or_silence

reading triple agonist threads from 2024 and half of it aged badly

Discussionbranch of 6 comments

Something I keep coming back to: reading triple agonist threads from 2024 and half of it aged badly. The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number. Nothing containing this compound is approved…

Read the full submission and all 64 comments →

This branch

6 comments, started 2 years ago
u/signe_villalobos329 points·2 years ago

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

replysharereportpermalink
[deleted]233 points·2 years ago

[deleted]

replysharereportpermalink
u/ewan_zielinski121 points·2 years ago

nothing here is available as a prescription product, so read every thread with that in mind

replysharereportpermalink
u/solene_ilunga-27 points·2 years ago

the energy-expenditure story is mechanistically interesting and clinically unproven

replysharereportpermalink
u/yannick_barros1 point·2 years ago

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

replysharereportpermalink
u/careful_gradient3296 points·2 years ago

a lot of the confident posting here is extrapolation

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.